• TRADE NAMES: Agrylin (Shire); Xagrid (Shire)
  • INDICATIONS: Essential thrombocytopenia; to reduce elevated platelet count and the risk of thrombosis
  • CLASS: Phospholipase A2 inhibitor
  • HALF-LIFE: 1.3 hours

Contraindicated in patients with severe hepatic impairment.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric